iC3b Antibody (Monoclonal - neoantigen)

A murine monoclonal antibody to a neo-epitope expressed on iC3b.


Product Specifications

Citations 26
Clonality

Monoclonal

Immunogen Purified human protein.
Applications See citations and technical data sheet for application info.
Concentration ≥ 1.0 mg/mL
Conjugate Unconjugated
Cross Reactivity

Human

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog Number A209
Catalog Number (CE) N/A
Size 100 µl
Price (USD) $365.00
Price (EURO) 330,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

A murine monoclonal antibody to a neo-epitope expressed on iC3b.

Size 100 µl
Concentration

≥ 1.0 mg/mL

Applications See citations and technical data sheet for application info.
Form Liquid. Borate Buffered Saline (pH 8.4 ± 0.2), with ≤ 0.1% Sodium Azide.
Clonality Monoclonal
Immunogen Purified human protein.
Conjugate Unconjugated
Cross Reactivity Human
Isotype IgG2bk
Purity > 95% by SDS PAGE
Source

Mouse

Specificity This monoclonal antibody was raised against purified human iC3b. It is specific for a neo-antigen on iC3b.
Storage

Short term (30 days) 4˚C. Long term at or below –20˚C.

Background

Under normal conditions, activation of either of the complement pathways leads to the formation of C3 convertase enzymes which cleave C3 into two fragments C3a, an anaphylatoxin, and C3b.The C3b fragment has many biologic functions including promotion of phagocytosis and participation as a structural component in both the C3 and C5 convertase enzymes. These processes are under stringent control in vivo. One control mechanism involves a two-site cleavage of C3b by Factor I with the cooperation of Factor H or CR1 as cofactors. When cleaved in this way the biologic functions of C3b are lost. The resulting protein is termed iC3b.This fragment, in turn, has a host of new biologic activities. iC3b fragments, either in fluid phase or bound to biological surfaces, can interact with a variety of cell types expressing complement receptors (either CR2 or CR3). iC3b levels in fluid phase are elevated in a variety of disease states including Systemic Lupus Erythematosis, Rheumatoid Arthritis as well as in a variety of pathologic conditions including sepsis and Myocardial Infarct. Quidel’s monoclonal antibodies to complement antigens were prepared using standard techniques. They are purified from mouse ascites fluid via protein A affinity chromatography. 3 The specificity of the monoclonal antibody was established via a series of immunological techniques including ELISA, hemagglutination and RIA. Firstly, the antibody was shown by ELISA to bind to C3 antigens using highly pure, immobilized C3. Subsequent studies showed that this antibody agglutinates EC3bi but not EC3b or EC3d cells in an indirect hemagglutination assay. Further experiments showed that this antibody bound to radio-labeled purified iC3b but not to similarly labeled C3, C3b, C3d, or C3c.

Citations

Title Year Applications Sample Species Sample Sample Details

Pneumolysin, PspA, and PspC Contribute to Pneumococcal Evasion of Early Innate Immune Responses During Bacteremia in Mice.

2007

WB

Bacteria

Pneumococci

Opsonization of apoptotic cells by autologous iC3b facilitates clearance by immature dendritic cells, down-regulates DR and CD86, and up-regulates CC chemokine receptor 7.

2002

Confocal Microscopy

Cell Culture

Jurkat Cells

Heme Interferes With Complement Factor I-Dependent Regulation by Enhancing Alternative Pathway Activation.

2021

ELISA

Human

Plasma

Sickel Cell Anemia

Complement Activation on Platelets Correlates with a Decrease in Circulating Immature Platelets in Patients with Immune Thrombocytopenic Purpura

2009

ELISA

Human

Plasma

Arabinosylation of recombinant human immunoglobulin-based protein therapeutics

2017

ELISA

Human

Serum

Inhibition of Immune Complex Complement Activation and Neutrophil Extracellular Trap Formation by Peptide Inhibitor of Complement C1.

2018

ELISA

Human

Serum

A monoclonal antibody targeting amyloid β (Aβ) restores complement factor I bioactivity: Potential implications in age-related macular degeneration and Alzheimer's disease

2018

ELISA

Human

Plasma

Age-Related Macular Degeneration

A monoclonal antibody targeting amyloid β (Aβ) restores complement factor I bioactivity: Potential implications in age-related macular degeneration and Alzheimer's disease

2018

ELISA

Human

Plasma

Alzheimer's Disease

Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide.

1998

ELISA

Human

Amyloid-βeta peptides & NHS

Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.

2013

FC

Human

HUVEC Cells

aHUS

Bacillus anthracis Spore Surface Protein BclA Mediates Complement Factor H Binding to Spores and Promotes Spore Persistence.

2016

FC

Human

Serum

B. anthracis incubated

Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.

2017

FC

Human

Red Blood Cells

PNH

Complement Receptor 3 Has Negative Impact on Tumor Surveillance through Suppression of Natural Killer Cell Function

2017

FC

Human

NK Cells

Complement activation in the Parkinson’s disease substantia nigra: an immunocytochemical study.

2006

ICC, IHC

Human

Brain Tissue

Plaque complement activation and cognitive loss in Alzheimer’s disease.

2008

ICC, IHC

Human

Brain Tissue

Sequential Increase in Complement Factor I, iC3b, and Cells Expressing CD11b or CD14 in Cutaneous Vasculitis.

2022

IHC

Human

Skin Tissue

Cutaneous Vasculitis

Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis.

2000

IHC

Human

Brain Tissue

Fetal

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases

2011

IHC

Human

Lung Tissue

Asthmatic Alzheimer's

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases

2011

IHC

Human

Lung Tissue

Tumor necrosis-initiated complement activation stimulates proliferation of medulloblastoma cells.

2015

IHC

Human

Brain Tissue

Medullablastoma

quantitative lateral flow assay to detect complement activation in blood.

2015

Lateral Flow Assay

Human

Plasma

Complement receptor 3 mediates Aspergillus fumigatus internalization into alveolar epithelial cells with the increase of intracellular phosphatidic acid by activating FAK.

2021

WB

Human

Serum

Aspergillus incubated

Efficient complement-mediated clearance of immunosuppressed T cells by macrophages.

2023

IF

Human

T Cells

Immunosuppressed

Increased expression of complement C3c, iC3b and cells containing CD11b or CD14 in experimentally induced psoriatic lesion

2024

IHC

Human

Skin Tissue

Psoriasis

Increased expression of complement C3c, iC3b and cells containing CD11b or CD14 in experimentally induced psoriatic lesion

2024

ICC

Human

Keratinocytes

Psoriasis

Control of Entamoeba histolytica adherence involves metallosurface protease 1, an M8 family surface metalloprotease with homology to leishmanolysin.

2012

FC

Parasite

Entamoeba histolytica